Clinical trial
Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients
NCT04910295 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients
- Lead sponsor
- Seoul National University Hospital
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 26, 2021
- Completion date
- December 31, 2022
- Enrollment
- 112 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cancer, covid19